• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

与系统性硬化症相关的住院治疗以及间质性肺疾病的影响。对在美国密歇根大学住院的患者进行分析。

Hospitalisations related to systemic sclerosis and the impact of interstitial lung disease. Analysis of patients hospitalised at the University of Michigan, USA.

机构信息

Department of Medicine, William Beaumont Hospital, Royal Oak, USA.

Division of Rheumatology, Department of Medicine, University of Michigan Medical School, Ann Arbor, USA.

出版信息

Clin Exp Rheumatol. 2021 Jul-Aug;39 Suppl 131(4):43-51. doi: 10.55563/clinexprheumatol/9ivp9g. Epub 2021 Mar 10.

DOI:10.55563/clinexprheumatol/9ivp9g
PMID:33734968
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8324531/
Abstract

OBJECTIVES

To determine the primary reason for hospitalisations in systemic sclerosis (SSc) and impact of underlying interstitial lung disease (ILD) in a tertiary scleroderma centre.

METHODS

A retrospective analysis on a subset of a scleroderma cohort from 2011-2019 was performed to assess causes for hospitalisations and mortality. A chart review was performed to extract demographics, primary reason for hospitalisation and inpatient mortality. Admissions were classified as SSc (if hospitalisation reason was related to primary organ dysfunction) and non-SSc related causes.

RESULTS

The mean age of the cohort was 53.1 years, 78% were women, and the mean disease duration was 5.2 years. Among 484 patients, 182 (37.6%) were admitted for a total of 634 admissions. In 382 SSc-related admissions, pulmonary hypertension (12.0%) and gastrointestinal dysmotility (11.0%), were major causes of urgent admissions; management of digital vasculopathy (26.1%) was the major reason for elective admissions. In 252 non-SSc related admissions, infection (respiratory:11.5%, skin and soft tissue: 6.3%) was the major reason for urgent admissions, and elective surgery (21.4%) was the major reason for elective admissions. We found 65% of all patients had underlying ILD and a greater proportion of patients with ILD were hospitalised (122 patients). Overall inpatient mortality was 9.3% and the leading cause for mortality was progressive pulmonary hypertension.

CONCLUSIONS

Among a large cohort of SSc patients who are followed at a tertiary scleroderma centre, 37.6 % had hospital admissions, while worsening pulmonary hypertension, ILD, cardiac involvement and infectious complications were the major cause of mortality and morbidity.

摘要

目的

确定系统性硬化症(SSc)住院的主要原因,并评估潜在间质性肺病(ILD)对三级硬皮病中心患者的影响。

方法

对 2011 年至 2019 年期间硬皮病队列的一个亚组进行回顾性分析,以评估住院和死亡的原因。通过病历回顾提取人口统计学、住院主要原因和住院死亡率。将住院分为 SSc(如果住院原因与主要器官功能障碍有关)和非 SSc 相关原因。

结果

该队列的平均年龄为 53.1 岁,78%为女性,平均病程为 5.2 年。在 484 名患者中,182 名(37.6%)因总共 634 次住院而入院。在 382 例与 SSc 相关的住院中,肺动脉高压(12.0%)和胃肠动力障碍(11.0%)是紧急入院的主要原因;数字血管病变的治疗(26.1%)是择期入院的主要原因。在 252 例非 SSc 相关的住院中,感染(呼吸道:11.5%,皮肤和软组织:6.3%)是紧急入院的主要原因,择期手术(21.4%)是择期入院的主要原因。我们发现所有患者中有 65%患有潜在的ILD,且患有ILD 的患者比例更高(122 名)。总的住院死亡率为 9.3%,导致死亡的主要原因是进行性肺动脉高压。

结论

在一家三级硬皮病中心接受治疗的大量 SSc 患者中,有 37.6%的患者住院,而肺动脉高压恶化、ILD、心脏受累和感染并发症是导致发病率和死亡率的主要原因。

相似文献

1
Hospitalisations related to systemic sclerosis and the impact of interstitial lung disease. Analysis of patients hospitalised at the University of Michigan, USA.与系统性硬化症相关的住院治疗以及间质性肺疾病的影响。对在美国密歇根大学住院的患者进行分析。
Clin Exp Rheumatol. 2021 Jul-Aug;39 Suppl 131(4):43-51. doi: 10.55563/clinexprheumatol/9ivp9g. Epub 2021 Mar 10.
2
Mortality and hospitalization outcomes of interstitial lung disease and pulmonary hypertension in the Singapore systemic sclerosis cohort.新加坡系统性硬化症队列中间质性肺病和肺动脉高压的死亡率和住院结局。
Semin Arthritis Rheum. 2020 Jun;50(3):473-479. doi: 10.1016/j.semarthrit.2019.11.005. Epub 2019 Nov 13.
3
Acute hospitalization in a cohort of patients with systemic sclerosis: a 10-year retrospective cohort study.系统性硬化症患者队列的急性住院治疗:一项 10 年回顾性队列研究。
Rheumatol Int. 2022 Aug;42(8):1393-1402. doi: 10.1007/s00296-021-04983-4. Epub 2021 Sep 3.
4
Pulmonary Artery Dimensions as a Prognosticator of Transplant-Free Survival in Scleroderma Interstitial Lung Disease.肺动脉尺寸作为硬皮病相关性间质性肺疾病患者移植后无生存的预测指标。
Lung. 2017 Aug;195(4):403-409. doi: 10.1007/s00408-017-0005-6. Epub 2017 Apr 29.
5
Economic Burden of Illness Among Commercially Insured Patients with Systemic Sclerosis with Interstitial Lung Disease in the USA: A Claims Data Analysis.美国商业保险系统性硬化症伴间质性肺病患者的疾病经济负担:一项理赔数据分析。
Adv Ther. 2019 May;36(5):1100-1113. doi: 10.1007/s12325-019-00929-2. Epub 2019 Mar 30.
6
All-cause Healthcare Costs and Mortality in Patients with Systemic Sclerosis with Lung Involvement.系统性硬化症肺部受累患者的全因医疗保健费用和死亡率。
J Rheumatol. 2018 Feb;45(2):235-241. doi: 10.3899/jrheum.170307. Epub 2017 Nov 15.
7
Scleroderma lung disease.硬皮病肺疾病。
Clin Rev Allergy Immunol. 2011 Apr;40(2):104-16. doi: 10.1007/s12016-009-8194-2.
8
Evaluation and management approaches for scleroderma lung disease.硬皮病肺病的评估与管理方法
Ther Adv Respir Dis. 2017 Aug;11(8):327-340. doi: 10.1177/1753465817713680. Epub 2017 Jun 16.
9
Determinants of morbidity and mortality of systemic sclerosis in Canada.加拿大系统性硬化症发病率和死亡率的决定因素。
Semin Arthritis Rheum. 2010 Feb;39(4):269-77. doi: 10.1016/j.semarthrit.2008.06.002. Epub 2008 Aug 15.
10
Interstitial lung disease in systemic sclerosis: data from the spanish scleroderma study group.系统性硬化症的间质性肺疾病:来自西班牙硬皮病研究组的数据。
Rheumatol Int. 2018 Mar;38(3):363-374. doi: 10.1007/s00296-017-3916-x. Epub 2018 Jan 10.

引用本文的文献

1
Hospitalizations in patients with systemic sclerosis: Differences between limited and diffuse cutaneous subtypes.系统性硬化症患者的住院情况:局限性和弥漫性皮肤亚型之间的差异。
J Scleroderma Relat Disord. 2024 Dec 11:23971983241299294. doi: 10.1177/23971983241299294.
2
The impact of hospitalization on mortality in patients with connective tissue disease-associated interstitial lung disease: a medical records review study.结缔组织病相关间质性肺疾病患者住院对死亡率的影响:一项病历回顾研究。
Adv Rheumatol. 2024 Jan 2;64(1):1. doi: 10.1186/s42358-023-00343-x.
3
Trends in Hospitalization Duration for Rare Diseases: A Retrospective Analysis of Sarcoidosis, Still's Disease, and Systemic Sclerosis in Poland (2009-2018).

本文引用的文献

1
Management of systemic sclerosis: the first five years.系统性硬化症的管理:前五年。
Curr Opin Rheumatol. 2020 May;32(3):228-237. doi: 10.1097/BOR.0000000000000711.
2
Current and Future Outlook on Disease Modification and Defining Low Disease Activity in Systemic Sclerosis.当前和未来对系统性硬化症疾病修饰和低疾病活动度的展望。
Arthritis Rheumatol. 2020 Jul;72(7):1049-1058. doi: 10.1002/art.41246. Epub 2020 May 18.
3
Management of systemic sclerosis-associated interstitial lung disease in the current era.当代系统性硬化症相关间质性肺疾病的管理
罕见病住院时间趋势分析:波兰结节病、斯蒂尔病和系统性硬化症的回顾性分析(2009-2018 年)。
Med Sci Monit. 2023 Nov 20;29:e941536. doi: 10.12659/MSM.941536.
4
Heterogeneity of determining disease severity, clinical course and outcomes in systemic sclerosis-associated interstitial lung disease: a systematic literature review.系统性硬皮病相关间质性肺病疾病严重程度、临床病程和结局的判断异质性:系统文献回顾。
RMD Open. 2023 Nov;9(4). doi: 10.1136/rmdopen-2023-003426.
5
Recent innovations in the screening and diagnosis of systemic sclerosis-associated interstitial lung disease.系统性硬皮病相关间质性肺疾病的筛查和诊断的最新进展。
Expert Rev Clin Immunol. 2023 Jun;19(6):613-626. doi: 10.1080/1744666X.2023.2198212. Epub 2023 Apr 10.
6
Risk factors for lung function decline in systemic sclerosis-associated interstitial lung disease in a large single-centre cohort.系统性硬皮病相关间质性肺病患者肺功能下降的危险因素:一项大型单中心队列研究。
Rheumatology (Oxford). 2023 Jul 5;62(7):2501-2509. doi: 10.1093/rheumatology/keac639.
7
Improving outcomes in scleroderma: recent progress of cell-based therapies.改善硬皮病的预后:基于细胞的治疗方法的最新进展。
Rheumatology (Oxford). 2023 Jun 1;62(6):2060-2069. doi: 10.1093/rheumatology/keac628.
8
Systemic sclerosis associated interstitial lung disease: a conceptual framework for subclinical, clinical and progressive disease.系统性硬皮病相关性间质性肺病:亚临床、临床和进展性疾病的概念框架。
Rheumatology (Oxford). 2023 May 2;62(5):1877-1886. doi: 10.1093/rheumatology/keac557.
Int J Rheum Dis. 2020 Feb;23(2):137-139. doi: 10.1111/1756-185X.13799.
4
Etiology, Risk Factors, and Biomarkers in Systemic Sclerosis with Interstitial Lung Disease.系统性硬化症伴间质性肺病的病因、危险因素和生物标志物。
Am J Respir Crit Care Med. 2020 Mar 15;201(6):650-660. doi: 10.1164/rccm.201903-0563CI.
5
Mortality and hospitalization outcomes of interstitial lung disease and pulmonary hypertension in the Singapore systemic sclerosis cohort.新加坡系统性硬化症队列中间质性肺病和肺动脉高压的死亡率和住院结局。
Semin Arthritis Rheum. 2020 Jun;50(3):473-479. doi: 10.1016/j.semarthrit.2019.11.005. Epub 2019 Nov 13.
6
One year in review 2019: systemic sclerosis.2019 年回顾:系统性硬化症。
Clin Exp Rheumatol. 2019 Jul-Aug;37 Suppl 119(4):3-14. Epub 2019 Oct 3.
7
Impact of the revised haemodynamic definition on the diagnosis of pulmonary hypertension in patients with systemic sclerosis.修订后的血流动力学定义对系统性硬化症患者肺动脉高压诊断的影响。
Eur Respir J. 2019 Aug 22;54(2). doi: 10.1183/13993003.00586-2019. Print 2019 Aug.
8
Management of systemic sclerosis-associated interstitial lung disease.系统性硬皮病相关间质性肺疾病的管理。
Curr Opin Rheumatol. 2019 May;31(3):241-249. doi: 10.1097/BOR.0000000000000592.
9
Prevalence, Treatment, and Outcomes of Coexistent Pulmonary Hypertension and Interstitial Lung Disease in Systemic Sclerosis.特发性肺纤维化合并肺动脉高压患者的临床特征、治疗及预后。
Arthritis Rheumatol. 2019 Aug;71(8):1339-1349. doi: 10.1002/art.40862. Epub 2019 Jun 18.
10
Trends in Demographics, Hospitalization Outcomes, Comorbidities, and Mortality Risk among Systemic Sclerosis Patients.系统性硬化症患者的人口统计学、住院结局、合并症及死亡风险趋势
Cureus. 2018 May 14;10(5):e2628. doi: 10.7759/cureus.2628.